StageZero Life Sciences Ltd.
SZLSF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.07 | 0.61 | 0.01 |
| FCF Yield | -80.12% | -55.97% | -11.96% | -612.47% |
| EV / EBITDA | -0.60 | -2.80 | -3.71 | -1.29 |
| Quality | ||||
| ROIC | 151.84% | -122.86% | -67.61% | 654.69% |
| Gross Margin | -10.64% | 23.23% | 16.75% | -692.78% |
| Cash Conversion Ratio | 0.31 | 1.20 | 0.45 | 1.32 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.95% | 231.83% | 181.63% | -30.42% |
| Free Cash Flow Growth | 61.24% | -190.21% | 32.33% | -40.73% |
| Safety | ||||
| Net Debt / EBITDA | -0.17 | 0.06 | 0.48 | -0.98 |
| Interest Coverage | -27.27 | -39.75 | -5.34 | -6.37 |
| Efficiency | ||||
| Inventory Turnover | 43.91 | 9.52 | 9.74 | 12.53 |
| Cash Conversion Cycle | -233.95 | -21.43 | -79.93 | -362.85 |